HYUNDAI BIOSCIENCE
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD 2024-09-18 09:26
Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue 2024-09-11 14:25
Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization 2024-08-28 17:29
ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy' 2024-07-11 14:07
Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever 2024-06-26 09:17
Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil 2024-04-25 21:41
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer 2024-04-25 17:11
Hyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer 2024-04-22 17:51
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization 2024-04-19 13:17
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization 2024-04-19 10:54
A 'Game Changer' COVID-19 drug from Korea was introduced in a world class academic journal 2021-05-24 08:16
An oral antiviral drug from Korea may be a problem solver for COVID-19 2021-05-13 16:37
CNPharm has succeeded in maintaining IC100 for 24 hours with one injection 2021-04-19 20:15
Hyundai Bioscience leads in the repurposing of Niclosamide 2021-04-08 17:17
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19 2020-12-23 10:09
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem 2020-12-08 21:00
Hyundai Bioscience: A Korean bio-tech solves the bioavailability issue of Niclosamide 2020-10-29 20:00
'Curing Cancer without Surgery' 2020-06-30 15:10
1